Key among them was the promotion of Brad Calvin to the role of chief commercial officer after a successful stint as the cell therapy specialist’s vice president of commercial operations.
In his former role, Calvin oversaw the sales, marketing and business development functions and MaxCyte said he helped “define product strategy, deliver new products and drove the growth of its drug discovery and cell therapy businesses”.
Specifically, he led the successful launch of the ExPERT platform, a family of instruments used in complex cellular engineering.
In a statement, MaxCyte chief executive Doug Doerfler said: “Brad’s promotion is well-earned and important for MaxCyte’s future growth. Since joining MaxCyte in 2017, he has forged pivotal relationships with leading cell therapy and gene editing companies, leading to multiple successful clinical and commercial agreements.
MaxCyte announced two further appointments – Sarah Haecker Meeks, who has joined as vice president, business development, while Steve Nardi has been appointed vice president of the firm’s manufacturing and engineering operations.
“Sarah’s extensive corporate development experience across the gene and cell therapy sector and Steve’s broad knowledge of innovative manufacturing strategy and R&D will help MaxCyte continue to extend the reach of its next-generation cell engineering technologies,” said CEO Doerfler.
“These technologies hold great promise for global drug development companies working on breakthrough therapies for patients.”